# KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial

> **NCT05635591** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Tongji Hospital** · enrollment: 9 (estimated)

## Conditions studied

- EBV-associated Haematologic Neoplasms

## Interventions

- **BIOLOGICAL:** Autologous monocyte - derived DCs pulsed with EBV antigen

## Key facts

- **NCT ID:** NCT05635591
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-01-16
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05635591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05635591, "KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05635591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*